GlassScriptPhysician profile
Brittney Mason
NPI 1295124600
$1,106.37
in general payments reported to CMS, 2019-2025
15 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.52 · 2020: $73.17 · 2021: $269 · 2022: $119 · 2023: $186 · 2024: $233 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $314.61 | 2019-2025 | |
| Astellas Pharma US INC | $187.75 | 2023-2025 | Veozah |
| Coopersurgical, INC. | $116.32 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.85 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $83.75 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $65.42 | 2023-2025 | Myfembree |
| Hologic Sales and Service, LLC | $53.73 | 2024-2025 | Aptima, Thinprep 2000 Processor, Acessa Provu System |
| Exeltis, USA INC. | $31.53 | 2022-2025 | Slynd |
| Avion Pharmaceuticals | $30.54 | 2021-2023 | Balcoltra |
| Millicent US INC | $29.75 | 2024-2025 | Femring, Intrarosa, Femlyv |
| Organon LLC | $27.46 | 2022-2024 | |
| Pfizer INC. | $27.09 | 2023-2024 | |
| Mylan Pharmaceuticals INC. | $23.40 | 2021 | |
| Lupin INC. | $15.75 | 2020 | |
| Merck Sharp & Dohme LLC | $13.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittney Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.